Canine mammary carcinoma: current therapeutic targets and future perspectives

Canine mammary carcinoma: current therapeutic targets and future perspectives – a review

Published:2023-07-01 Issue:3 Volume:23 Page:703-716
ISSN:2300-8733
Container-title:Annals of Animal Science
language:en
Short-container-title:

Author:

Nordin Muhammad Luqman¹²,Azemi Ahmad Khusairi³⁴,Ismail Noraznawati³,Nordin Abu Hassan⁵⁶,Nabgan Walid⁵,Noralidin Nur Amalina¹,Shaari Rumaizi¹,Rajdi Nur Zul Izzati Mohd¹,Reduan Mohd Farhan Hanif¹,Siti Hawa Nordin⁷,Rasool Aida Hanum Ghulam⁴,Ibrahim Nik Nor Izah Nik⁴

Affiliation:

1. 1 Department of Veterinary Clinical Studies, Faculty of Veterinary Medicine , Universiti Malaysia Kelantan , Pengkalan Chepa, 16100 Kota Bharu , Kelantan , Malaysia

2. 2 Centre for Drug Delivery Technology, Faculty of Pharmacy , Universiti Kebangsaan Malaysia (UKM) Kuala Lumpur Campus , Jalan Raja Muda Abdul Aziz, Kuala Lumpur, 50300 , Malaysia

3. 3 Institure of Marine Biotechnology , Universiti Malaysia Terengganu , 21030 Kuala Terengganu, Terengganu , Malaysia

4. 4 Department of Pharmacology, School of Medical Sciences , Universiti Sains Malaysia (Health Campus) , 16150 Kota Bharu, Kelantan , Malaysia

5. 5 School of Chemical and Energy Engineering, Faculty of Engineering , Universiti Teknologi Malaysia , 81310, Skudai, Johor , Malaysia

6. 6 Faculty of Applied Sciences , Universiti Teknologi MARA (UiTM) , 02600 Arau, Perlis , Malaysia

7. 7 Pharmacology Unit, School of Basic Medical Sciences, Faculty of Medicine , Universiti Sultan Zainal Abidin , Kuala Terengganu 20400 , Malaysia

Abstract

Abstract Canine mammary carcinoma (CMC) is the most common neoplasm in bitches, and it shares many biological similarities with breast cancer in humans. Drug resistance, high epigenetic mutations, and relapse rates are among the challenges which eventually urge the need for a veterinary oncologist to discover new therapeutic approaches that are more effective and safer. Therefore, in this review, we also cover the current therapeutic strategies from human medicine for the future perspectives of tumor immunotherapy in veterinary medicine. These strategies have great potential to be employed as therapeutic or prophylactic options due to their ability to modulate a specific and potent immune response against CMC. As we acquire a better understanding of canine tumor immunology, we can move towards a brighter prognosis. Additionally, we report on the recent successful studies in breast cancer that may benefit canines as well.

Publisher

Walter de Gruyter GmbH

Link

https://www.sciendo.com/pdf/10.2478/aoas-2022-0085

Reference160 articles.

1. Abdelmegeed S.M., Mohammed S. (2018). Canine mammary tumors as a model for human disease. Oncol. Lett., 15: 8195–8205.

2. Abubakar M., Guo C., Koka H., Sung H., Shao N., Guida J., Deng J., Li M., Hu N., Zhou B., Lu N., Yang X.R. (2019). Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression. NPJ Breast Cancer, 5: 1–9.

3. Ahern T.E., Bird R.C., Bird A.E., Wolfe L.G. (1996). Expression of the oncogene c-erbB-2 in canine mammary cancers and tumorderived cell lines. Am. J. Vet. Res., 57: 693–696.

4. Al-Mansour M.A., Kubba M.A., Al-Azreg S.A., Dribika S.A. (2018). Comparative histopathology and immunohistochemistry of human and canine mammary tumors. Open Vet. J., 8: 243–249.

5. Anguille S., Smits E.L., Bryant C., Van Acker H.H., Goossens H., Lion E., Fromm P.D., Hart D.N., Van Tendeloo V.F., Berneman Z.N. (2015). Dendritic cells as pharmacological tools for cancer immunotherapy. Pharm. Rev., 67: 731–753.